JP2022505925A5 - - Google Patents
Info
- Publication number
- JP2022505925A5 JP2022505925A5 JP2021523011A JP2021523011A JP2022505925A5 JP 2022505925 A5 JP2022505925 A5 JP 2022505925A5 JP 2021523011 A JP2021523011 A JP 2021523011A JP 2021523011 A JP2021523011 A JP 2021523011A JP 2022505925 A5 JP2022505925 A5 JP 2022505925A5
- Authority
- JP
- Japan
- Prior art keywords
- invention described
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862754383P | 2018-11-01 | 2018-11-01 | |
| US62/754,383 | 2018-11-01 | ||
| PCT/US2019/059555 WO2020093023A1 (en) | 2018-11-01 | 2019-11-01 | Anti-tim-3 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022505925A JP2022505925A (ja) | 2022-01-14 |
| JP2022505925A5 true JP2022505925A5 (cg-RX-API-DMAC7.html) | 2022-11-08 |
Family
ID=69159931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523011A Pending JP2022505925A (ja) | 2018-11-01 | 2019-11-01 | 抗tim-3抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220081480A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3873611A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022505925A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113272017A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019371457A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3117429A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL282707A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020093023A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7214440B2 (ja) * | 2018-11-01 | 2023-01-30 | 三菱重工エンジニアリング株式会社 | 検証処理装置、検証処理方法及びプログラム |
| JPWO2023286854A1 (cg-RX-API-DMAC7.html) * | 2021-07-16 | 2023-01-19 | ||
| TW202327649A (zh) * | 2021-09-15 | 2023-07-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | Pvrig/tigit結合蛋白聯合免疫檢查點抑制劑用於治療癌症 |
| WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
| WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
| CN119654339A (zh) | 2022-07-01 | 2025-03-18 | 特兰斯吉恩股份有限公司 | 包含表面活性蛋白-d和tnfsf成员的融合蛋白 |
| WO2025202222A1 (en) | 2024-03-25 | 2025-10-02 | Institut National de la Santé et de la Recherche Médicale | Therapeutic use of sting and tlrs agonists to induce p16 expression in immune cells |
| WO2026059950A1 (en) * | 2024-09-10 | 2026-03-19 | Agilent Technologies, Inc. | Anti-human tim3 antibodies for in vitro diagnostics |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5179689B2 (ja) | 2000-02-11 | 2013-04-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗体ベース融合タンパク質の循環系内半減期の増強 |
| DK1366067T3 (da) | 2001-03-07 | 2012-10-22 | Merck Patent Gmbh | Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed |
| US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
| US8993524B2 (en) | 2010-03-05 | 2015-03-31 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| PL3099717T3 (pl) | 2014-01-31 | 2019-10-31 | Novartis Ag | Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie |
| HRP20210977T1 (hr) | 2014-02-10 | 2021-09-17 | Merck Patent Gmbh | Ciljano inhibiranje tgf beta |
| AU2015340056A1 (en) * | 2014-10-27 | 2017-05-25 | Agency For Science, Technology And Research | Anti-TIM-3 antibodies |
| US20180153986A1 (en) * | 2015-04-24 | 2018-06-07 | The Brigham And Women's Hospital, Inc. | Interactions between ceacam and tim family members |
| US20180207273A1 (en) * | 2015-07-29 | 2018-07-26 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
| PT3370768T (pt) * | 2015-11-03 | 2022-04-21 | Janssen Biotech Inc | Anticorpos que se ligam especificamente ao pd-1 e seus usos |
| US20190248893A1 (en) * | 2016-07-14 | 2019-08-15 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
| JOP20190013A1 (ar) * | 2016-08-25 | 2019-01-31 | Lilly Co Eli | أجسام مضادة لـ (تي آي ام -3) |
| MA50677A (fr) * | 2016-11-01 | 2021-07-14 | Anaptysbio Inc | Anticorps dirigés contre la protéine d'immunoglobuline de lymphocytes t et mucine 3 (tim-3) |
| TWI665216B (zh) * | 2016-12-29 | 2019-07-11 | 財團法人生物技術開發中心 | 抗人類tim-3抗體及其使用方法 |
| AU2018205401B2 (en) * | 2017-01-09 | 2025-01-02 | Tesaro, Inc. | Methods of treating cancer with anti-TIM-3 antibodies |
| CN110050000B (zh) | 2017-05-12 | 2022-07-26 | 苏州盛迪亚生物医药有限公司 | 含有TGF-β受体的融合蛋白及其医药用途 |
-
2019
- 2019-11-01 CA CA3117429A patent/CA3117429A1/en active Pending
- 2019-11-01 CN CN201980086657.5A patent/CN113272017A/zh active Pending
- 2019-11-01 WO PCT/US2019/059555 patent/WO2020093023A1/en not_active Ceased
- 2019-11-01 EP EP19835889.7A patent/EP3873611A1/en not_active Withdrawn
- 2019-11-01 AU AU2019371457A patent/AU2019371457A1/en not_active Abandoned
- 2019-11-01 JP JP2021523011A patent/JP2022505925A/ja active Pending
-
2021
- 2021-04-27 IL IL282707A patent/IL282707A/en unknown
- 2021-04-30 US US17/245,474 patent/US20220081480A1/en not_active Abandoned